Prime Medicine, Inc.(PRME)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,481 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
PRME Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Prime Medicine, Inc. (PRME), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PRME at 30.7/100 on a 32-signal composite quality model, placing it at rank #2,481 of 2,962 stocks — the bottom half of the AI-ranked universe. PRME scores in the top quartile across revenue growth (97.9). Areas of concern include free cash flow (0.9) and profitability (1.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 1.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Prime Medicine, Inc. reports net income of $-42.1M, free cash flow of $-41.1M. Top institutional holders of PRME by reported 13-F value include Alphabet, BlackRock, ARK Investment Management, based on the most recent SEC filings. PRME trades on the Nasdaq exchange and files with the SEC under CIK 1894562. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PRME daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Prime Medicine, Inc. directly from SEC EDGAR. Prime Medicine, Inc.'s 13F Pro composite quality score has ranged between 9 and 31 since 2025, currently 30.7 — an improving long-term trajectory across 52 quarterly and live scoring snapshots.
Net Income
Q2 2026
$-42.1M
Free Cash Flow
Q2 2026
$-41.1M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+55.3% YoYNet Income
-2.7% YoYOperating Income
-2.9% YoYEPS (Diluted)
+18.2% YoYTotal Assets
+15.2% YoYOp. Cash Flow
-32.3% YoYFree Cash Flow
-28.4% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $4.6M +55.3% | $3.0M | $0.00 | $0.00 | $0.00 -100.0% | $5.2M |
| Net Income | $-201.1M -2.7% | $-195.9M +1.1% | $-198.1M -62.6% | $-121.8M +26.3% | $-165.4M -4749.5% | $-3.4M |
| Operating Income | $-208.3M -2.9% | $-202.5M +1.1% | $-204.8M -75.7% | $-116.5M -38.0% | $-84.5M -8963.7% | $-932.0K |
| EPS (Diluted) | $-1.35 +18.2% | $-1.65 +24.3% | $-2.18 +48.0% | $-4.19 +11.4% | $-4.73 -642.9% | $-0.64 |
| Total Assets | $342.7M +15.2% | $297.5M +53.5% | $193.9M -46.2% | $360.3M +19.4% | $301.9M | — |
| Operating Cash Flow | $-162.6M -32.3% | $-122.9M +25.7% | $-165.4M -25.5% | $-131.8M -286.8% | $-34.1M -514.8% | $-5.5M |
| Free Cash Flow | $-167.1M -28.4% | $-130.2M +25.3% | $-174.1M -17.7% | $-147.9M -286.9% | $-38.2M -518.3% | $-6.2M |
Get alerted when PRME's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Prime Medicine, Inc. including:
Top Institutional Holders of PRME
Alphabet Inc.
$61.1M16,562,498 shBlackRock, Inc.
$35.4M9,602,041 shARK Investment Management LLC
$30.8M8,348,746 shSTATE STREET CORP
$28.0M7,576,460 shT. Rowe Price Investment Management, Inc.
$19.3M5,237,332 shVANGUARD CAPITAL MANAGEMENT LLC
$16.7M4,522,640 shBALYASNY ASSET MANAGEMENT L.P.
$14.6M3,969,082 shGOLDMAN SACHS GROUP INC
$12.7M3,430,518 shCasdin Capital, LLC
$11.7M3,167,175 shWoodline Partners LP
$11.1M3,003,904 sh
| Fund | Value | Shares |
|---|---|---|
| Alphabet Inc. | $61.1M | 16,562,498 |
| BlackRock, Inc. | $35.4M | 9,602,041 |
| ARK Investment Management LLC | $30.8M | 8,348,746 |
| STATE STREET CORP | $28.0M | 7,576,460 |
| T. Rowe Price Investment Management, Inc. | $19.3M | 5,237,332 |
| VANGUARD CAPITAL MANAGEMENT LLC | $16.7M | 4,522,640 |
| BALYASNY ASSET MANAGEMENT L.P. | $14.6M | 3,969,082 |
| GOLDMAN SACHS GROUP INC | $12.7M | 3,430,518 |
| Casdin Capital, LLC | $11.7M | 3,167,175 |
| Woodline Partners LP | $11.1M | 3,003,904 |
Companies Similar to PRME
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Beam Therapeutics Inc.
CG Oncology, Inc.
Kura Oncology, Inc.
Invivyd, Inc.
Lyell Immunopharma, Inc.
Atai Beckley N.V.
Janux Therapeutics, Inc.
PRECIGEN, INC.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put PRME on your watchlist
Track score changes the day Prime Medicine, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is PRME a good stock to buy?
13F Pro's AI-powered analysis of Prime Medicine, Inc. (PRME) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PRME are available on the PRME stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. PRME is classified as a small company.
Which hedge funds own PRME?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PRME. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Prime Medicine, Inc.'s investment landscape.